» Articles » PMID: 2054784

Potentiation of 1-beta-D-arabinofuranosylcytosine Cytotoxicity to HL-60 Cells by 1,25-dihydroxyvitamin D3 Correlates with Reduced Rate of Maturation of DNA Replication Intermediates

Overview
Journal Cancer Res
Specialty Oncology
Date 1991 Jul 1
PMID 2054784
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

S-phase-active cytotoxic drugs selectively damage leukemic cells, but the mechanisms of this action are not clear. We have investigated the previously reported potentiation of toxicity of 1-beta-D-arabinofuranosylcytosine (ara-C) to HL-60 cells by the differentiation-inducing steroid, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], and compared the results with the effects of other drugs which inhibit DNA synthesis. Determination of the intracellular content of the active metabolite of ara-C, ara-CTP, excluded more prolonged retention of the drug as the basis for potentiation of cytotoxicity. Alkaline elution of replicating DNA showed that 1,25(OH)2D3 added with or immediately after ara-C or hydroxyurea reduced the rate maturation of the replicating DNA and resulted in an increased proportion of smaller DNA fragments. However, pretreatment of the cells with 1,25(OH)2D3 inhibited this effect of the drugs on replication of DNA. No direct effect of 1,25(OH)2De on replicating DNA could be detected. The results suggest that the early events which initiate cell differentiation may protect an intact DNA replicative machinery from S-phase-active drugs but reduce the rate of DNA maturation once DNA integrity has been compromised by inhibitors of DNA synthesis.

Citing Articles

Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.

Wang X, Harrison J, Studzinski G J Steroid Biochem Mol Biol. 2015; 164:72-78.

PMID: 26319201 PMC: 4769988. DOI: 10.1016/j.jsbmb.2015.08.023.


Cell-Type-Specific Effects of Silibinin on Vitamin D-Induced Differentiation of Acute Myeloid Leukemia Cells Are Associated with Differential Modulation of RXRα Levels.

Wassermann R, Novik V, Danilenko M Leuk Res Treatment. 2012; 2012:401784.

PMID: 23259067 PMC: 3505927. DOI: 10.1155/2012/401784.


Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance.

Chen-Deutsch X, Studzinski G Cell Cycle. 2012; 11(7):1364-73.

PMID: 22421156 PMC: 3350877. DOI: 10.4161/cc.19765.


MicroRNA-32 upregulation by 1,25-dihydroxyvitamin D3 in human myeloid leukemia cells leads to Bim targeting and inhibition of AraC-induced apoptosis.

Gocek E, Wang X, Liu X, Liu C, Studzinski G Cancer Res. 2011; 71(19):6230-9.

PMID: 21816906 PMC: 5572464. DOI: 10.1158/0008-5472.CAN-11-1717.


Vitamin D in combination cancer treatment.

Ma Y, Trump D, Johnson C J Cancer. 2010; 1:101-7.

PMID: 20842231 PMC: 2938072. DOI: 10.7150/jca.1.101.